Bone Metastasis - Pipeline Review, H1 2018

  • ID: 4518502
  • Drug Pipelines
  • 103 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Ablynx NV
  • Amgen Inc
  • BiologicsMD Inc
  • Eli Lilly and Co
  • Lupin Ltd
  • Mirati Therapeutics Inc
  • MORE
Bone Metastasis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H1 2018, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

Report Highlights:

This latest pipeline guide Bone Metastasis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 4, 1 and 18 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ablynx NV
  • Amgen Inc
  • BiologicsMD Inc
  • Eli Lilly and Co
  • Lupin Ltd
  • Mirati Therapeutics Inc
  • MORE
Introduction

Report Coverage

Bone Metastasis - Overview

Bone Metastasis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bone Metastasis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bone Metastasis - Companies Involved in Therapeutics Development

Ablynx NV

Amgen Inc

BiologicsMD Inc

CSPC Pharmaceutical Group Limited

Deciphera Pharmaceuticals LLC

Eli Lilly and Co

Lupin Ltd

MabVax Therapeutics Holdings Inc

Mirati Therapeutics Inc

Oncobiologics Inc

Oncodrone BV

OPKO Health Inc

R Pharm

Serene LLC

Taiho Pharmaceutical Co Ltd

Terpenoid Therapeutics Inc

Bone Metastasis - Drug Profiles

ADM-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALX-0141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BKM-1644 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BKM-1740 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMD-3151 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

calcifediol ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCC-3014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Osteomyelitis and Bone Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emibetuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LG-1980 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

merestinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Connexin 43 for Breast Cancer and Bone Metastasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit JAG1 for Bone Metastasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCD-155 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPH-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSF-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSF-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sitravatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tin-117m-DTPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPH-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vicrostatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bone Metastasis - Dormant Projects

Bone Metastasis - Discontinued Products

Bone Metastasis - Product Development Milestones

Featured News & Press Releases

Jan 05, 2018: NeuClone Discloses Details of its Fifth Product: A Biosimilar Candidate for Prolia/XGEVA (Denosumab)

Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease

May 24, 2011: Daiichi Sankyo and AstraZeneca Announce a Co-Promotion Agreement in Japan for Denosumab, a Treatment of Bone Disorders stemming from Bone Metastasis

May 18, 2011: Amgen To Present XGEVA Data At ASCO Annual Meeting

Dec 10, 2010: Amgen Presents New XGEVA Breast Cancer Skeletal-Related Event Prevention Data At SABCS

Nov 18, 2010: Amgen Receives FDA Approval for XGEVA For Prevention Of Skeletal-Related Events In Patients With Bone Metastases From Solid Tumors

Nov 08, 2010: Amgen Announces Phase III Study Results Of Denosumab In Breast Cancer Patients With Bone Metastases

Nov 08, 2010: Published Results Show Denosumab Superior to Zometa in Delaying or Preventing Bone Complications in Patients with Bone Metastases From Advanced Breast Cancer

Oct 11, 2010: Amgen Reports Integrated Analysis Demonstrates That Denosumab Delays Onset Of Bone Complications Compared To Zometa

Jul 17, 2010: Amgen Receives FDA's Priority Review Designation For Denosumab BLA For Reduction Of Skeletal Related Events In Advanced Cancer Patients

May 14, 2010: Amgen Submits Denosumab BLA To FDA For Reduction Of Skeletal Related Events In Cancer Patients

Aug 03, 2009: Amgen Announces Positive Top-Line Results For Denosumab In Bone Metastases Patients Compared To Zometa

Jun 04, 2006: Amgen Announces Phase 2 Interim Data Of Denosumab In Advanced Cancer Patients With Bone Metastases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Bone Metastasis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Bone Metastasis - Pipeline by Ablynx NV, H1 2018

Bone Metastasis - Pipeline by Amgen Inc, H1 2018

Bone Metastasis - Pipeline by BiologicsMD Inc, H1 2018

Bone Metastasis - Pipeline by CSPC Pharmaceutical Group Limited, H1 2018

Bone Metastasis - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018

Bone Metastasis - Pipeline by Eli Lilly and Co, H1 2018

Bone Metastasis - Pipeline by Lupin Ltd, H1 2018

Bone Metastasis - Pipeline by MabVax Therapeutics Holdings Inc, H1 2018

Bone Metastasis - Pipeline by Mirati Therapeutics Inc, H1 2018

Bone Metastasis - Pipeline by Oncobiologics Inc, H1 2018

Bone Metastasis - Pipeline by Oncodrone BV, H1 2018

Bone Metastasis - Pipeline by OPKO Health Inc, H1 2018

Bone Metastasis - Pipeline by R Pharm, H1 2018

Bone Metastasis - Pipeline by Serene LLC, H1 2018

Bone Metastasis - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018

Bone Metastasis - Pipeline by Terpenoid Therapeutics Inc, H1 2018

Bone Metastasis - Dormant Projects, H1 2018

Bone Metastasis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Bone Metastasis - Dormant Projects, H1 2018 (Contd..2), H1 2018

Bone Metastasis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Bone Metastasis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Ablynx NV
  • Amgen Inc
  • BiologicsMD Inc
  • CSPC Pharmaceutical Group Limited
  • Deciphera Pharmaceuticals LLC
  • Eli Lilly and Co
  • Lupin Ltd
  • MabVax Therapeutics Holdings Inc
  • Mirati Therapeutics Inc
  • Oncobiologics Inc
  • Oncodrone BV
  • OPKO Health Inc
  • R Pharm
  • Serene LLC
  • Taiho Pharmaceutical Co Ltd
  • Terpenoid Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll